https://katieregan.journoportfolio.comRSS Feed for Katie ReganenSat, 15 Aug 2026 00:00:00 +0100https://www.rna-coop.org/portal/public/overviewProgram home page. I wrote all web copy.Sat, 15 Aug 2026 00:00:00 +0100https://www.rna-coop.org/portal/public/overviewhttps://www.path.org/who-we-are/programs/center-for-vaccine-innovation-and-access/strengthening-the-global-vaccine-supply/Home page for PATH's Sustaining Vaccine Manufacturing website. I designed the page and wrote and maintain all the content.Sat, 15 Aug 2026 00:00:00 +0100https://www.path.org/who-we-are/programs/center-for-vaccine-innovation-and-access/strengthening-the-global-vaccine-supply/https://www.path.org/our-impact/media-center/multivalent-meningococcal-meningitis-vaccine-from-serum-institute-of-india-achieves-who-prequalification/Pune, India, and Seattle, United States – MenFive®, the first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO).Developed through a 13-year collaboration between Serum Institute of India Pvt. Ltd. (SIIPL) and PATH, with crucial funding from the UK government’s Foreign, Commonwealth and Development Office, MenFive® protects against meningococcal serogroups A, C, W, Y, and X and is de...Fri, 14 Aug 2026 00:00:00 +0100https://www.path.org/our-impact/media-center/multivalent-meningococcal-meningitis-vaccine-from-serum-institute-of-india-achieves-who-prequalification/https://www.path.org/our-impact/articles/breaking-the-taboo-on-including-pregnant-women-in-vaccine-clinical-trials/Pregnant women need better data to confidently access lifesaving vaccines. We’re improving meningitis vaccine access with a new clinical study of MenFive® in pregnant and breastfeeding women. This study broadens our commitment to maternal health by prioritizing action toward a longstanding knowledge gap. Pregnant women are no less susceptible to disease than non-pregnant people; they should have no less access to lifesaving vaccines.Mon, 27 Jul 2026 00:00:00 +0100https://www.path.org/our-impact/articles/breaking-the-taboo-on-including-pregnant-women-in-vaccine-clinical-trials/https://www.path.org/our-impact/articles/china-expands-hpv-vaccination/Bivalent human papillomavirus (HPV) vaccine is now included in the country’s national immunization program (NIP), ensuring girls across China can access this essential tool for preventing cervical cancer. In China, HPV vaccines have been available on the private market since 2016. Despite this, only an estimated 4 percent of girls between 9 and 14 years of age (the target age range for HPV vaccination recommended by the World Health Organization [WHO]) were vaccinated against the disease in 2022—and China reported the world’s highest numbers of cervical cancer cases and second highest number of cervical cancer deaths.Mon, 01 Jun 2026 00:00:00 +0100https://www.path.org/our-impact/articles/china-expands-hpv-vaccination/https://media.path.org/documents/GBS_fact_sheet_Jan2026_TQXrHSI.pdf?_gl=1*j9gbs4*_gcl_au*MTQ5MjkwNjQ5OC4xNzg2NTg2NjU5*_ga*MTY3MTEzOTMwLjE3ODY1ODY2NTk.*_ga_YBSE7ZKDQM*czE3ODY5NDM5NDkkbzE5JGcxJHQxNzg2OTQ0MjkwJGo1NSRsMCRoMA..Fact sheet describing PATH’s work to develop a vaccine against Group B Streptococcus.Mon, 05 Jan 2026 00:00:00 +0000https://media.path.org/documents/GBS_fact_sheet_Jan2026_TQXrHSI.pdf?_gl=1*j9gbs4*_gcl_au*MTQ5MjkwNjQ5OC4xNzg2NTg2NjU5*_ga*MTY3MTEzOTMwLjE3ODY1ODY2NTk.*_ga_YBSE7ZKDQM*czE3ODY5NDM5NDkkbzE5JGcxJHQxNzg2OTQ0MjkwJGo1NSRsMCRoMA..https://media.path.org/documents/SVM_fact_sheet_case_studies_FINAL_Dec2025_7J0P8Wv.pdf?_gl=1*1as8v68*_gcl_au*MTQ5MjkwNjQ5OC4xNzg2NTg2NjU5*_ga*MTY3MTEzOTMwLjE3ODY1ODY2NTk.*_ga_YBSE7ZKDQM*czE3ODY3NzY4NjIkbzExJGcxJHQxNzg2Nzc2OTk2JGoxMSRsMCRoMA..Fact sheet highlighting program successes and impacts. For donors, manufacturers, and prospective partners.Mon, 01 Dec 2025 00:00:00 +0000https://media.path.org/documents/SVM_fact_sheet_case_studies_FINAL_Dec2025_7J0P8Wv.pdf?_gl=1*1as8v68*_gcl_au*MTQ5MjkwNjQ5OC4xNzg2NTg2NjU5*_ga*MTY3MTEzOTMwLjE3ODY1ODY2NTk.*_ga_YBSE7ZKDQM*czE3ODY3NzY4NjIkbzExJGcxJHQxNzg2Nzc2OTk2JGoxMSRsMCRoMA..https://media.path.org/documents/PATH_HealthEcon_FactSheet_Kenya_R3_A4.pdfFact sheet summarizing the results of a vaccine cost-of-delivery study for policy advisors, public health professionals, and government leaders in Kenya.Mon, 03 Nov 2025 00:00:00 +0000https://media.path.org/documents/PATH_HealthEcon_FactSheet_Kenya_R3_A4.pdfhttps://media.journoportfolio.com/users/517873/uploads/6fb38972-3f98-4215-b3c1-caf9211f57a8.pdfSlide deck promoting SVM program to funders, potential partners, manufacturers, and other stakeholders.Wed, 01 Oct 2025 00:00:00 +0100https://media.journoportfolio.com/users/517873/uploads/6fb38972-3f98-4215-b3c1-caf9211f57a8.pdfhttps://www.path.org/our-impact/articles/how-one-path-project-advanced-the-global-hpv-prevention-landscape/PATH’s HPV Vaccine Safety, Immunogenicity, and Health Economics (HPV SIHE) project is coming to a close after five years—and it leaves a long list of successes behind. Cervical cancer is the fourth most common cancer among women globally, with more than 95 percent of cases resulting from human papillomavirus (HPV) infection. HPV vaccines are highly effective; since their introduction, they have significantly reduced the incidence of HPV infections and precancerous cervical lesions. But although they have been available since 2006, HPV vaccines remain out of reach for many girls and women in low- and middle-income countries (LMICs)—where about 94 percent of cervical cancer deaths globally occur.Mon, 21 Jul 2025 00:00:00 +0100https://www.path.org/our-impact/articles/how-one-path-project-advanced-the-global-hpv-prevention-landscape/https://www.path.org/our-impact/articles/a-deadly-disease-for-infants-has-no-vaccinewere-changing-that/Group B Streptococcus is a leading cause of sepsis and meningitis in young infants worldwide. It can even lead to problems during pregnancy, causing miscarriage, premature delivery, and stillbirth.Fri, 18 Jul 2025 00:00:00 +0100https://www.path.org/our-impact/articles/a-deadly-disease-for-infants-has-no-vaccinewere-changing-that/https://www.tandfonline.com/doi/full/10.1080/21645515.2025.2559506#d1e298Co-author on peer-reviewed publication describing MenFive meningitis vaccine development. I also coordinated the writing, editing, timeline, and co-author communication.Tue, 24 Jun 2025 00:00:00 +0100https://www.tandfonline.com/doi/full/10.1080/21645515.2025.2559506#d1e298https://www.path.org/our-impact/articles/supporting-vaccine-manufacturers-supply-critical-vaccines/Imagine a country wants to introduce a vaccine to protect its population from a serious disease, but the doses are either not available for purchase or so expensive they are out of reach. Imagine this happens during a disease outbreak or epidemic—or even a pandemic. Country leaders would be prevented from providing essential vaccine to their citizens and saving lives.Sound familiar? It’s exactly what happened during the COVID-19 pandemic, when low- and lower-middle-income countries across the wo...Wed, 26 Feb 2025 00:00:00 +0000https://www.path.org/our-impact/articles/supporting-vaccine-manufacturers-supply-critical-vaccines/https://www.path.org/our-impact/articles/whats-next-for-meningitis-prevention-more-vaccine-options/The meningococcal meningitis prevention landscape has transformed in the last 15 years with the introduction of affordable, effective vaccines to the African meningitis belt. But we need more to ensure sustainable access. Meningococcal meningitis is swift and often lethal and, for decades, reliable vaccines were out of reach for the African countries that suffer the greatest disease burden.Tue, 28 Jan 2025 00:00:00 +0000https://www.path.org/our-impact/articles/whats-next-for-meningitis-prevention-more-vaccine-options/https://www.clintonhealthaccess.org/report/how-has-the-african-vaccine-manufacturing-landscape-changed-in-the-last-year/Published by Africa CDC. Africa has long relied on other parts of the world for its vaccine supply. This inequitable global health structure creates barriers to access, leaving the continent vulnerable to threats like the COVID-19 pandemic. African leaders have voiced this struggle for years, but Africa’s delay in receiving COVID-19 vaccines thrust the issue onto the global stage. It prompted African leaders to create the Partnerships for African Vaccine Manufacturing and formalize a goal of locally manufacturing 60 per...Fri, 18 Oct 2024 00:00:00 +0100https://www.clintonhealthaccess.org/report/how-has-the-african-vaccine-manufacturing-landscape-changed-in-the-last-year/https://www.path.org/our-impact/articles/how-has-the-african-vaccine-manufacturing-landscape-changed-in-the-last-year/Published by PATH. Africa has long relied on other parts of the world for its vaccine supply. This inequitable global health structure creates barriers to access and leaves the continent vulnerable to threats like the COVID-19 pandemic. African leaders have voiced this struggle for years, but the delay Africa faced in receiving COVID-19 vaccines thrust the issue onto the global stage. It prompted African leaders to create the Partnership for African Vaccine Manufacturing with an ambitious goal of locally manufactu...Fri, 18 Oct 2024 00:00:00 +0100https://www.path.org/our-impact/articles/how-has-the-african-vaccine-manufacturing-landscape-changed-in-the-last-year/https://www.path.org/our-impact/media-center/new-hpv-vaccine-from-zerun-bio-receives-who-prequalification/Walrinvax™, a bivalent human papillomavirus (HPV) vaccine, has been prequalified by the World Health Organization (WHO). Walrinvax is manufactured by Yuxi Zerun Biotechnology Co., Ltd. in Yuxi City, Yunnan Province, China, a fully owned subsidiary of Shanghai Zerun Biotechnology under Walvax Biotechnology Co., Ltd. Walrinvax is designed to protect against HPV types 16 and 18, the most common virus types that lead to cervical cancer. Countries facing barriers to national introduction or strugglin...Thu, 29 Aug 2024 00:00:00 +0100https://www.path.org/our-impact/media-center/new-hpv-vaccine-from-zerun-bio-receives-who-prequalification/https://www.path.org/our-impact/articles/a-new-vaccine-could-stop-meningitis-epidemics-in-africafor-good/When MenAfriVac® was introduced in Burkina Faso in 2010, we predicted the end of meningococcal meningitis wouldn’t be far behind. It was a bold assertion; for more than a century, the disease had reigned freely in the 26 countries that make up Africa’s meningitis belt, causing debilitating annual epidemics that, at their largest, would claim tens of thousands of lives in a single season. But just three years after introducing MenAfriVac®—which targeted serogroup A meningococcal meningitis, then the most prevalent serogroup (think, “strain”)—disease incidence had dropped by 94 percent in vaccinated areas and today, meningitis A has effectively been eliminated from the meningitis belt.Wed, 12 Jun 2024 00:00:00 +0100https://www.path.org/our-impact/articles/a-new-vaccine-could-stop-meningitis-epidemics-in-africafor-good/https://www.meningitis.org/news-and-blogs/a-new-vaccine-could-end-meningitis-epidemics-in-africa/Vaccines are the best way to prevent meningococcal meningitis. But in Africa’s meningitis belt, a string of 26 countries from Senegal and The Gambia in the west to Ethiopia in the east that suffers the highest global burden of the disease, effective vaccines have all-too-often been out of reach. The 2010 introduction of MenAfriVac® – developed by Serum Institute of India, in partnership with PATH and the World Health Organization (WHO) – changed everything. MenAfriVac® is the groundbreaking affo...Tue, 14 May 2024 00:00:00 +0100https://www.meningitis.org/news-and-blogs/a-new-vaccine-could-end-meningitis-epidemics-in-africa/https://www.path.org/our-impact/articles/is-hpv-vaccination-cost-effective/Cervical cancer is highly preventable with human papillomavirus (HPV) vaccines, but cost is one of the biggest considerations countries face when determining whether a vaccine will have sustainable impact.Thu, 14 Mar 2024 00:00:00 +0000https://www.path.org/our-impact/articles/is-hpv-vaccination-cost-effective/https://www.sciencedirect.com/science/article/pii/S0264410X22012129?CMX_ID=&SIS_ID=&dgcid=STMJ_AUTH_SERV_PUBLISHED&utm_acid=81296051&utm_campaign=STMJ_AUTH_SERV_PUBLISHED&utm_in=DM389854&utm_medium=email&utm_source=AC_Co-author on peer-reviewed publication assessing the value of RSV prevention interventions to help guide global decision-makers.Fri, 03 Nov 2023 00:00:00 +0000https://www.sciencedirect.com/science/article/pii/S0264410X22012129?CMX_ID=&SIS_ID=&dgcid=STMJ_AUTH_SERV_PUBLISHED&utm_acid=81296051&utm_campaign=STMJ_AUTH_SERV_PUBLISHED&utm_in=DM389854&utm_medium=email&utm_source=AC_https://media.path.org/documents/Meningitis_fact_sheet_November2023.pdf?_gl=1*7wq36j*_gcl_au*MTQ5MjkwNjQ5OC4xNzg2NTg2NjU5*_ga*MTY3MTEzOTMwLjE3ODY1ODY2NTk.*_ga_YBSE7ZKDQM*czE3ODY4NjMwNzMkbzE0JGcxJHQxNzg2ODYzMjc5JGo1JGwwJGgwFact sheet describing PATH’s efforts to advance new and better vaccines against meningococcal meningitis.Wed, 01 Nov 2023 00:00:00 +0000https://media.path.org/documents/Meningitis_fact_sheet_November2023.pdf?_gl=1*7wq36j*_gcl_au*MTQ5MjkwNjQ5OC4xNzg2NTg2NjU5*_ga*MTY3MTEzOTMwLjE3ODY1ODY2NTk.*_ga_YBSE7ZKDQM*czE3ODY4NjMwNzMkbzE0JGcxJHQxNzg2ODYzMjc5JGo1JGwwJGgwhttps://africacdc.org/news-item/what-will-it-take-to-develop-a-sustainable-vaccine-manufacturing-ecosystem-in-africa/A study of Africa’s current and planned vaccine manufacturing capacity offers insights into how to target investments and development efforts to promote long-term success. Africa is largely reliant on other regions of the world for lifesaving vaccines. Currently, only one percent of the vaccines administered in Africa are produced locally; the remaining 99 percent are imported. Such an imbalance in production can contribute to unequal access to needed vaccines and enormous health disparities...Wed, 04 Oct 2023 00:00:00 +0100https://africacdc.org/news-item/what-will-it-take-to-develop-a-sustainable-vaccine-manufacturing-ecosystem-in-africa/https://www.path.org/our-impact/media-center/african-vaccine-manufacturing-capacity-is-a-mixed-picture-formfillfinish-capacity-is-strong-while-end-to-end-local-vaccine-production-will-require-additional-investment/New analysis illuminates strengths, gaps, opportunities, and recommendations for building a sustainable vaccine manufacturing ecosystem.Thu, 21 Sep 2023 00:00:00 +0100https://www.path.org/our-impact/media-center/african-vaccine-manufacturing-capacity-is-a-mixed-picture-formfillfinish-capacity-is-strong-while-end-to-end-local-vaccine-production-will-require-additional-investment/https://www.path.org/our-impact/articles/what-will-it-take-to-develop-a-sustainable-vaccine-manufacturing-ecosystem-in-africa/Africa is largely reliant on other regions of the world for lifesaving vaccines. Currently, only one percent of the vaccines administered in Africa are produced locally; the remaining 99 percent are imported. Such an imbalance in production can contribute to unequal access to needed vaccines and enormous health disparities between regions.The tide is turning, however; investment in African vaccine manufacturing has surged in recent years as Africa works to safeguard itself against future pandemi...Thu, 21 Sep 2023 00:00:00 +0100https://www.path.org/our-impact/articles/what-will-it-take-to-develop-a-sustainable-vaccine-manufacturing-ecosystem-in-africa/https://media.path.org/documents/AVM_mapping_briefing_paper_091823_FINAL.pdf?_gl=1*1yes6vv*_gcl_au*ODcxODUyMzcuMTc4NjY0Nzk0Ng..*_ga*NjgzOTA0MjI4LjE3ODY2NDc5NDY.*_ga_YBSE7ZKDQM*czE3ODY2NzYwNTkkbzQkZzEkdDE3ODY2ODY5NzMkajYwJGwwJGgwBriefing paper detailing the results of a manufacturing capacity landscape assessment for investors, policy makers, African governments, NGOs, and manufacturers.Tue, 01 Aug 2023 00:00:00 +0100https://media.path.org/documents/AVM_mapping_briefing_paper_091823_FINAL.pdf?_gl=1*1yes6vv*_gcl_au*ODcxODUyMzcuMTc4NjY0Nzk0Ng..*_ga*NjgzOTA0MjI4LjE3ODY2NDc5NDY.*_ga_YBSE7ZKDQM*czE3ODY2NzYwNTkkbzQkZzEkdDE3ODY2ODY5NzMkajYwJGwwJGgwhttps://www.path.org/our-impact/media-center/multivalent-meningococcal-meningitis-vaccine-from-serum-institute-of-india-achieves-who-prequalification/MenFive®, the first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO).Developed through a 13-year collaboration between Serum Institute of India Pvt. Ltd. (SIIPL) and PATH, with crucial funding from the UK government’s Foreign, Commonwealth and Development Office, MenFive® protects against meningococcal serogroups A, C, W, Y, and X and is de...Wed, 12 Jul 2023 00:00:00 +0100https://www.path.org/our-impact/media-center/multivalent-meningococcal-meningitis-vaccine-from-serum-institute-of-india-achieves-who-prequalification/https://www.path.org/our-impact/media-center/serum-institutes-acwyx-vaccine-candidate-demonstrates-strong-safety-and-immunogenicity/Detailed results from a Phase 3 study of Serum Institute of India Pvt. Ltd.'s (SIIPL's) NmCV-5 vaccine candidate, a conjugate vaccine designed to protect against meningococcal serogroups A, C, W, Y, and X, were published in the New England Journal of Medicine.Meningococcal meningitis, a type of bacterial meningitis, is one of the most feared diseases in Africa. It is responsible for deadly annual outbreaks and epidemics that have led to tens of thousands of cases and thousands of deaths each yea...Thu, 25 May 2023 00:00:00 +0100https://www.path.org/our-impact/media-center/serum-institutes-acwyx-vaccine-candidate-demonstrates-strong-safety-and-immunogenicity/https://www.path.org/our-impact/media-center/new-panel-of-antibodies-specific-to-sars-cov-2-variants-available-for-vaccine-researchers/PATH, Texas Children’s Hospital Center for Vaccine Development, Baylor College of Medicine, and the Medicines and Healthcare products Regulatory Agency (MHRA) have collaborated to provide variant-specific monoclonal antibodies (mAbs) against the receptor-binding domain (RBD) of SARS-CoV-2 variants. These mAbs can support researchers globally during the characterization and development of vaccines for current and evolving variants of SARS-CoV-2.Through this collaboration, scientists from Texas Ch...Tue, 23 May 2023 00:00:00 +0100https://www.path.org/our-impact/media-center/new-panel-of-antibodies-specific-to-sars-cov-2-variants-available-for-vaccine-researchers/https://www.path.org/our-impact/articles/reaching-cervical-cancer-elimination-goals-with-hpv-vaccines/Even before the COVID-19 pandemic, countries with low- and middle-income (LMIC) economies faced numerous financial and logistical barriers to HPV vaccine uptake. Entry of new, low-cost HPV vaccines into the global market could increase access, especially in the countries that face the most significant burdens.To that end, PATH is supporting a Phase 3 clinical study of Cecolin®, a bivalent HPV vaccine manufactured by Xiamen Innovax Biotech Co., Ltd., which received WHO prequalification in 2021. (...Thu, 27 Apr 2023 00:00:00 +0100https://www.path.org/our-impact/articles/reaching-cervical-cancer-elimination-goals-with-hpv-vaccines/